ASHER BIOTHERAPEUTICS, INC.

Profile

Company Names

ASHER BIOTHERAPEUTICS, INC.

Addresses

650 GATEWAY BLVD., SUITE 100, SOUTH SAN FRANCISCO, CA 94080

288 AVALON DRIVE, SOUTH SAN FRANCISCO, CA 94080

Phone Numbers

617-953-3949
617 953-3949

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2019

State Incorporated:

DELAWARE

Total Amount Raised:

$163,489,965.00

Number of Funding Rounds:

3
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
3
2024-04-03 
$54,999,990.00 
$54,999,990.00 
$0.00 
Equity 
2
2021-08-20 
$107,999,975.00 
$107,999,975.00 
$0.00 
Equity 
1
2019-08-19 
$490,000.00 
$3,000,000.00 
$2,510,000.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
IAN 
 
CLARK 
DIRECTOR
DICHOTOMY PARTNERS LP   |  AVROBIO, INC.   |  OLEMA PHARMACEUTICALS, INC.   |  GYROSCOPE THERAPEUTICS LTD   |  KYVERNA THERAPEUTICS, INC.   |  ASHER BIOTHERAPEUTICS, INC.
BOB 
 
DERESIEWICZ 
DIRECTOR
ASHER BIOTHERAPEUTICS, INC.
IVANA 
 
DJURETIC 
EXECUTIVE OFFICER, DIRECTOR, PROMOTER
ASHER BIOTHERAPEUTICS, INC.
KYLE 
 
ELROD 
EXECUTIVE OFFICER
ASHER BIOTHERAPEUTICS, INC.
CRAIG 
 
GIBBS 
EXECUTIVE OFFICER, DIRECTOR
ARIDIS PHARMACEUTICALS, INC.   |  ASHER BIOTHERAPEUTICS, INC.
REID 
 
HUBER 
DIRECTOR
THIRD ROCK VENTURES V, L.P.   |  ASHER BIOTHERAPEUTICS, INC.   |  THIRD ROCK VENTURES VI, L.P.   |  SYNNOVATION THERAPEUTICS, INC.   |  TANGO THERAPEUTICS, INC.   |  TERREMOTO BIOSCIENCES, INC.
DON 
 
O-SULLIVAN 
EXECUTIVE OFFICER
ASHER BIOTHERAPEUTICS, INC.
ELAINE 
 
SUN 
DIRECTOR
SUTROVAX, INC.   |  CIRIUS THERAPEUTICS, INC.   |  ASHER BIOTHERAPEUTICS, INC.
JEFFREY 
 
TONG 
DIRECTOR
THIRD ROCK VENTURES V, L.P.   |  ASHER BIOTHERAPEUTICS, INC.   |  THIRD ROCK VENTURES VI, L.P.   |  SEPTERNA, INC.
ANDY 
 
YEUNG 
EXECUTIVE OFFICER
ASHER BIOTHERAPEUTICS, INC.
YIK ANDY 
 
YEUNG 
EXECUTIVE OFFICER, DIRECTOR, PROMOTER
ASHER BIOTHERAPEUTICS, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2024-04-16
D
Link
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
DECLINE TO DISCLOSE 
Equity 
2024-04-03 
2021-09-07
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2021-08-20 
2019-09-05
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2019-08-19 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#